At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Yohimbinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant
In Brief
A Phase 2 clinical trial evaluating Yohimbine for Type 2 Diabetes. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The investigators have recently discovered a genetic variant in an adrenergic receptor that leads to increased risk for type 2 diabetes. The investigators have also seen that blockers of that receptor improves impaired insulin secretion in animals. The investigators will now test the blocker in patients with type 2 diabetes with or without the risk variant in an effort to make diabetes treatment more individualized.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesSweden
CollaboratorsRegion Skane, Lund University
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedMay 2012
Primary CompletionOct 2014
TodayJul 2026
First PostedMay 8, 2012
Enrollment StartMay 1, 2012
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 14.2 years ago
Interventions
Yohimbinedrug
Yohimbine capsule